Clinical Trial Update: A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

The Phase I/II clinical trial of GMX1777 in combination with temozolomide for metastatic melanoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GMX1777 (GMX1777)
• Temodar (Temozolomide)

Snippet

Sponsor: Gemin X | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: TERMINATED